FI101678B - Happolabiileja kytkentämolekyylejä - Google Patents

Happolabiileja kytkentämolekyylejä

Info

Publication number
FI101678B
FI101678B FI916131A FI916131A FI101678B FI 101678 B FI101678 B FI 101678B FI 916131 A FI916131 A FI 916131A FI 916131 A FI916131 A FI 916131A FI 101678 B FI101678 B FI 101678B
Authority
FI
Finland
Prior art keywords
aralkyl
aryl
lower alkyl
alkylene
alkyl
Prior art date
Application number
FI916131A
Other languages
English (en)
Swedish (sv)
Other versions
FI101678B1 (fi
FI916131A (fi
FI916131A0 (fi
Inventor
Petrus Johannes Boon
Franciscus Michael Kaspersen
Ebo Sybren Bos
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of FI916131A0 publication Critical patent/FI916131A0/fi
Publication of FI916131A publication Critical patent/FI916131A/fi
Application granted granted Critical
Publication of FI101678B1 publication Critical patent/FI101678B1/fi
Publication of FI101678B publication Critical patent/FI101678B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60Two oxygen atoms, e.g. succinic anhydride
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/24Condensed ring systems having three or more rings
    • C07H15/252Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mushroom Cultivation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI916131A 1990-12-31 1991-12-27 Happolabiileja kytkentämolekyylejä FI101678B (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90203526 1990-12-31

Publications (4)

Publication Number Publication Date
FI916131A0 FI916131A0 (fi) 1991-12-27
FI916131A FI916131A (fi) 1992-07-01
FI101678B1 FI101678B1 (fi) 1998-08-14
FI101678B true FI101678B (fi) 1998-08-14

Family

ID=8205218

Family Applications (1)

Application Number Title Priority Date Filing Date
FI916131A FI101678B (fi) 1990-12-31 1991-12-27 Happolabiileja kytkentämolekyylejä

Country Status (17)

Country Link
US (1) US5306809A (fi)
EP (1) EP0495265B1 (fi)
JP (1) JPH04334377A (fi)
KR (1) KR920012063A (fi)
AT (1) ATE109476T1 (fi)
AU (1) AU646121B2 (fi)
CA (1) CA2058595A1 (fi)
DE (1) DE69103255T2 (fi)
DK (1) DK0495265T3 (fi)
ES (1) ES2061166T3 (fi)
FI (1) FI101678B (fi)
HU (1) HUT60484A (fi)
IE (1) IE65406B1 (fi)
NO (1) NO180417C (fi)
NZ (1) NZ241217A (fi)
PT (1) PT99954B (fi)
ZA (1) ZA9110203B (fi)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505931A (en) * 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
EP0638583A1 (en) * 1993-08-13 1995-02-15 Hoechst Aktiengesellschaft Aminosugar active substances, a process for their preparation and use as pharmaceuticals
DE4433890C2 (de) * 1994-09-22 1999-02-18 Deutsches Krebsforsch Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein
PT871490E (pt) * 1995-12-22 2003-07-31 Bristol Myers Squibb Co Ligantes de hidrazona ramificada
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US6030997A (en) * 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
US6800616B2 (en) 1998-02-26 2004-10-05 Supergen, Inc. Treatment of HIV infections
CA2248592A1 (en) 1998-08-31 2000-02-29 Christopher D. Batich Microspheres for use in the treatment of cancer
TWI242000B (en) * 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
US6140015A (en) * 1998-12-10 2000-10-31 International Business Machines Corporation Photoresist compositions with pendant polar-functionalized aromatic groups and acid-labile branching
CA2358420C (en) * 1999-03-11 2010-03-16 Ardenia Investments Ltd. New compounds for the treatment of cancer
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
BRPI0003386B8 (pt) * 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
WO2002032400A1 (en) * 2000-10-16 2002-04-25 Neopharm, Inc. Liposomal formulation of mitoxantrone
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
GB0116143D0 (en) * 2001-07-02 2001-08-22 Amersham Pharm Biotech Uk Ltd Chemical capture reagent
KR100507968B1 (ko) * 2001-08-18 2005-08-17 한국과학기술연구원 자기집합체를 형성하는 항암제-키토산 복합체 및 그의제조방법
AU2002351388A1 (en) * 2001-12-14 2003-06-30 The University Of Wyoming Methods and compositions for controlled release of drugs
US8361464B2 (en) 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
US20050069551A1 (en) * 2002-03-08 2005-03-31 Emory University Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis
US20060229239A9 (en) * 2002-03-08 2006-10-12 Mamoru Shoji Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis
JP2005529931A (ja) * 2002-05-24 2005-10-06 マイラス コーポレイション 膜相互作用の可逆的改質
CN1733314A (zh) * 2004-08-11 2006-02-15 张阳德 半乳糖化白蛋白磁性阿霉素纳米粒的制备方法
WO2006052900A2 (en) * 2004-11-09 2006-05-18 University Of Southern California Targeted innate immunity
NZ556788A (en) 2005-01-05 2011-03-31 Biogen Idec Inc Humanized CRIPTO binding molecules with CDRs from murine B3F6
KR20090091145A (ko) 2006-10-27 2009-08-26 웨이-치앙 션 지질화된 인터페론 및 이의 용도
ES2609094T3 (es) * 2007-01-25 2017-04-18 Dana-Farber Cancer Institute, Inc. Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante
CA2680854C (en) * 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
MX2010001757A (es) 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
WO2010011684A2 (en) * 2008-07-21 2010-01-28 The Regents Of The University Of California Prodrug and fluoregenic compositions and methods for using the same
JP5472288B2 (ja) * 2009-03-17 2014-04-16 国立大学法人 東京大学 タンパク質の電荷調節剤、及びタンパク質内包高分子ミセル複合体
US8535948B2 (en) * 2009-03-26 2013-09-17 Institute For Systems Biology Method to determine protein interaction sites
US9290577B2 (en) 2009-07-03 2016-03-22 Avipep Pty Limited Immuno-conjugates and methods for producing them
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
WO2011075786A1 (en) 2009-12-23 2011-06-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
AU2011274229A1 (en) 2010-07-02 2013-01-10 Angiochem Inc. Short and D-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
CN103890246A (zh) 2011-08-18 2014-06-25 亲和生物科学公司 可溶性多肽
HUE039033T2 (hu) 2012-01-10 2018-12-28 Biogen Ma Inc Terápiás molekulák transzportjának fokozása a vér-agy gáton keresztül
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
WO2014057436A2 (en) 2012-10-10 2014-04-17 Adamed Sp. Z O.O. Anticancer conjugate
CN105209068A (zh) 2013-02-07 2015-12-30 免疫医疗公司 用于靶向癌症治疗的缀合至抗体的高效2-吡咯啉多柔比星的前药形式(p2pdox)
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
EP3104857A4 (en) 2014-02-14 2017-10-11 The Regents of The University of California Cyclic peroxides as prodrugs for selective delivery of agents
AU2015326407C1 (en) 2014-10-03 2021-06-24 Engeneic Molecular Delivery Pty Ltd Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
BR102016018074A2 (pt) 2015-08-07 2021-11-16 ALX Oncology Inc. Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
GEP20217326B (en) 2015-08-07 2021-11-25 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
PT3380495T (pt) 2015-11-24 2021-08-19 Transfert Plus Sec Compostos peptídicos e conjugados peptídicos para o tratamento de cancro através de quimioterapia mediada por recetores
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
EP3554638B1 (en) 2016-12-19 2022-02-02 Morehouse School of Medicine Compositions and methods for treating diseases by inhibiting exosome release
SG11202112733XA (en) 2019-05-31 2021-12-30 Alx Oncology Inc Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
KR20240007913A (ko) 2021-05-13 2024-01-17 알렉소 온콜로지 인크. 암 치료를 위한 병용 요법
US11180534B1 (en) 2021-06-04 2021-11-23 Morehouse School Of Medicine Compositions and methods for treating SARS-CoV-2 infections
AU2023208050A1 (en) * 2022-01-14 2024-07-04 Regeneron Pharmaceuticals, Inc. Verrucarin a derivatives and antibody drug conjugates thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4744981A (en) * 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US5140013A (en) * 1989-11-28 1992-08-18 Universite Laval Maleic anhydride derivatives used as conjugation agents of anti-tumor agents on desired carriers

Also Published As

Publication number Publication date
US5306809A (en) 1994-04-26
KR920012063A (ko) 1992-07-25
DK0495265T3 (da) 1995-01-02
NO180417C (no) 1997-04-16
IE65406B1 (en) 1995-10-18
FI101678B1 (fi) 1998-08-14
FI916131A (fi) 1992-07-01
DE69103255D1 (de) 1994-09-08
PT99954A (pt) 1993-06-30
NO180417B (no) 1997-01-06
ZA9110203B (en) 1993-01-27
NO920040D0 (no) 1992-01-02
JPH04334377A (ja) 1992-11-20
DE69103255T2 (de) 1994-12-08
ES2061166T3 (es) 1994-12-01
NZ241217A (en) 1993-12-23
HUT60484A (en) 1992-09-28
IE914567A1 (en) 1992-07-01
AU9009891A (en) 1993-01-28
AU646121B2 (en) 1994-02-10
PT99954B (pt) 1999-06-30
EP0495265B1 (en) 1994-08-03
CA2058595A1 (en) 1992-07-01
HU914133D0 (en) 1992-03-30
NO920040L (no) 1992-07-01
ATE109476T1 (de) 1994-08-15
FI916131A0 (fi) 1991-12-27
EP0495265A1 (en) 1992-07-22

Similar Documents

Publication Publication Date Title
FI101678B (fi) Happolabiileja kytkentämolekyylejä
MXPA03010432A (es) Inmunoconjugados del anticuerpo cd44 citotoxico.
KR900002803A (ko) 세포독성 약물 결합체
FI912285A0 (fi) Nya bifunktionella kopplingsfoereningar, konjugat och foerfaranden foer framstaellning av dessa.
ATE294592T1 (de) Thioether enthaltende konjugate
US4263279A (en) Pharmaceutically active compositions containing adriamycin and daunomycin
PT76394A (fr) Procede de preparation de nouveaux conjugues associant par liaison covalente une enzyme et un anticorps
IL64722A (en) Immunoglobulin conjugates,their preparation and pharmaceutical compositions containing them
FI915780A0 (fi) Maerktae, modifierade oligonukleotider.
WO2004041307A3 (en) Compositions and methods for treating cancer using cytotoxic cd44 antibody immunoconjugates and radiotherapy
HU9500585D0 (en) Hepatotropic conjugates of antiviral drugs, carriers thereof and pharmaceutical compositions containing them